Compare Novo Nordisk A/S (NVO) vs Transocean Ltd (RIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Transocean Ltd — how do they compare? Novo Nordisk A/S trades at $45.75 (market cap $207.85B), while Transocean Ltd trades at $5.8 (market cap $6.49B). The key difference: Novo Nordisk A/S is far larger — about 32× Transocean Ltd's market cap, and Novo Nordisk A/S pays a 3.81% dividend while Transocean Ltd pays none. Which is the better fit depends on your goals.
| NVO | RIG | |
|---|---|---|
Market Cap | $207.85B | $6.49B |
Sector | Health | Technology |
52-Week High | $63.98 | $7.58 |
52-Week Low | $35.29 | $2.80 |
Enterprise Value | $222.55B | $11.10B |
Dividend Yield | 3.81% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Transocean Ltd
Transocean Ltd. is a leading international provider of offshore contract drilling services for oil and gas wells. The company operates one of the world's most versatile fleets of mobile offshore drilling units, including ultra-deepwater drillships and harsh environment semi-submersibles. RIG's services are essential to energy exploration and production companies seeking to access deepwater and challenging reserves globally.
Read more on RIG →
